219 related articles for article (PubMed ID: 23251421)
21. Opacity-associated adhesin repertoire in hyperinvasive Neisseria meningitidis.
Callaghan MJ; Jolley KA; Maiden MC
Infect Immun; 2006 Sep; 74(9):5085-94. PubMed ID: 16926400
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R
Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872
[TBL] [Abstract][Full Text] [Related]
23. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A
Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703
[TBL] [Abstract][Full Text] [Related]
25. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines.
Heyderman RS; Davenport V; Williams NA
Trends Microbiol; 2006 Mar; 14(3):120-4. PubMed ID: 16469496
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
[TBL] [Abstract][Full Text] [Related]
27. FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression.
Sanders H; Norheim G; Chan H; Dold C; Vipond C; Derrick JP; Pollard AJ; Maiden MC; Feavers IM
PLoS One; 2015; 10(10):e0140345. PubMed ID: 26466091
[TBL] [Abstract][Full Text] [Related]
28. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
[TBL] [Abstract][Full Text] [Related]
29. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.
Marzoa J; Sánchez S; Costoya L; Diéguez-Casal E; Freixeiro P; Brookes C; Allen L; Taylor S; Gorringe AR; Ferreirós CM; Criado MT
Vaccine; 2012 Mar; 30(13):2387-95. PubMed ID: 21911024
[TBL] [Abstract][Full Text] [Related]
30. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
Gorringe AR; Taylor S; Brookes C; Matheson M; Finney M; Kerr M; Hudson M; Findlow J; Borrow R; Andrews N; Kafatos G; Evans CM; Read RC
Clin Vaccine Immunol; 2009 Aug; 16(8):1113-20. PubMed ID: 19553555
[TBL] [Abstract][Full Text] [Related]
31. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
Leduc I; Connolly KL; Begum A; Underwood K; Darnell S; Shafer WM; Balthazar JT; Macintyre AN; Sempowski GD; Duncan JA; Little MB; Rahman N; Garges EC; Jerse AE
PLoS Pathog; 2020 Dec; 16(12):e1008602. PubMed ID: 33290434
[TBL] [Abstract][Full Text] [Related]
32. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.
Moe GR; Zuno-Mitchell P; Hammond SN; Granoff DM
Infect Immun; 2002 Nov; 70(11):6021-31. PubMed ID: 12379678
[TBL] [Abstract][Full Text] [Related]
33. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial.
Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ
mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470
[TBL] [Abstract][Full Text] [Related]
34. Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae.
Humbert MV; Christodoulides M
Vaccine; 2018 Jun; 36(27):3926-3936. PubMed ID: 29803329
[TBL] [Abstract][Full Text] [Related]
35. Use of expanded
Borrow R; Martinón-Torres F; Abitbol V; Andani A; Preiss S; Muzzi A; Serino L; Sohn WY
Expert Rev Vaccines; 2023; 22(1):738-748. PubMed ID: 37622470
[TBL] [Abstract][Full Text] [Related]
36. Neisseria meningitidis B vaccines: recent advances and possible immunization policies.
Gasparini R; Amicizia D; Domnich A; Lai PL; Panatto D
Expert Rev Vaccines; 2014 Mar; 13(3):345-64. PubMed ID: 24476428
[TBL] [Abstract][Full Text] [Related]
37. Neisseria meningitidis serogroup B vaccine development.
Caesar NM; Myers KA; Fan X
Microb Pathog; 2013 Apr; 57():33-40. PubMed ID: 23416222
[TBL] [Abstract][Full Text] [Related]
38. Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.
Bielecka MK; Devos N; Gilbert M; Hung MC; Weynants V; Heckels JE; Christodoulides M
Infect Immun; 2015 Feb; 83(2):730-42. PubMed ID: 25452551
[TBL] [Abstract][Full Text] [Related]
39. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
40. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
